Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
| Autor: | Mark S. Silverberg, Mark A Samaan, Silvio Danese, Marla Dubinsky, G. Van Assche, Jaap Stoker, Iris Dotan, Sarah O’Donnell, Robert H. Riddell, Laurent Peyrin-Biroulet, Travis B. Murdoch, Brian G. Feagan, P. Marteau, Stephen B. Hanauer, Edward V. Loftus, Stefan Schreiber, Benjamin Pariente, David T. Rubin, S. Winer, Bruce E. Sands, Robert V Bryant, G R D’Haens, J.-F. Colombel, Simon Travis, S. Krishnareddy, Peter L. Lakatos, Walter Reinisch, Willem A. Bemelman, Gionata Fiorino, Richard B. Gearry, William J. Sandborn, Pia Munkholm, Guillaume Bouguen, Ingrid Ordás, J. Ruel, Julián Panés, Corey A. Siegel, Remo Panaccione |
|---|---|
| Přispěvatelé: | Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Clinic of Internal Medicine IV, Department of Gastroenterology and Hepathology, Universität Wien, AP-HP, Hôpital Lariboisière, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service des Maladies de l'Appareil Digestif [CHU Rennes], CHU Pontchaillou [Rennes], Hôpital Claude Huriez [Lille], CHU Lille, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service des Maladies de l'Appareil Digestif, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Surgery, Gastroenterology and Hepatology, Other departments, CCA -Cancer Center Amsterdam, Radiology and Nuclear Medicine, Peyrin-Biroulet, L, Sandborn, W, Sands, Be, Reinisch, W, Bemelman, W, Bryant, Rv, D'Haens, G, Dotan, I, Dubinsky, M, Feagan, B, Fiorino, G, Gearry, R, Krishnareddy, S, Lakatos, Pl, Loftus, Ev, Marteau, P, Munkholm, P, Murdoch, Tb, Ordas, I, Panaccione, R, Riddell, Rh, Ruel, J, Rubin, Dt, Samaan, M, Siegel, Ca, Silverberg, M, Stoker, J, Schreiber, S, Travis, S, Van Assche, G, Danese, S, Panes, J, Bouguen, G, O'Donnell, S, Pariente, B, Winer, S, Hanauer, S, Colombel, Jf |
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
Abdominal pain [SDV]Life Sciences [q-bio] Disease Inflammatory bowel disease 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Prospective cohort study Hepatology business.industry Remission Induction Gastroenterology Disease Management medicine.disease Inflammatory Bowel Diseases Ulcerative colitis 3. Good health Diarrhea 030220 oncology & carcinogenesis Practice Guidelines as Topic Physical therapy Biomarker (medicine) 030211 gastroenterology & hepatology medicine.symptom Calprotectin business |
| Zdroj: | The American Journal of Gastroenterology The American Journal of Gastroenterology, 2015, 110 (9), pp.1324-38. ⟨10.1038/ajg.2015.233⟩ American Journal of Gastroenterology American Journal of Gastroenterology, Nature Publishing Group: Open Access Hybrid Model Option A, 2015, 110 (9), pp.1324-38. ⟨10.1038/ajg.2015.233⟩ American journal of gastroenterology, 110(9), 1324-1338. Springer Nature |
| ISSN: | 1572-0241 0002-9270 |
| DOI: | 10.1038/ajg.2015.233⟩ |
| Popis: | International audience; OBJECTIVES: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a "treat-to-target" clinical management strategy using an evidence-based expert consensus process. METHODS: A Steering Committee of 28 IBD specialists developed recommendations based on a systematic literature review and expert opinion. Consensus was gained if ≥75% of participants scored the recommendation as 7-10 on a 10-point rating scale (where 10=agree completely). RESULTS: The group agreed upon 12 recommendations for ulcerative colitis (UC) and Crohn's disease (CD). The agreed target for UC was clinical/patient-reported outcome (PRO) remission (defined as resolution of rectal bleeding and diarrhea/altered bowel habit) and endoscopic remission (defined as a Mayo endoscopic subscore of 0-1). Histological remission was considered as an adjunctive goal. Clinical/PRO remission was also agreed upon as a target for CD and defined as resolution of abdominal pain and diarrhea/altered bowel habit; and endoscopic remission, defined as resolution of ulceration at ileocolonoscopy, or resolution of findings of inflammation on cross-sectional imaging in patients who cannot be adequately assessed with ileocolonoscopy. Biomarker remission (normal C-reactive protein (CRP) and calprotectin) was considered as an adjunctive target. CONCLUSIONS: Evidence- and consensus-based recommendations for selecting the goals for treat-to-target strategies in patients with IBD are made available. Prospective studies are needed to determine how these targets will change disease course and patients' quality of life.Am J Gastroenterol advance online publication, 25 August 2015; doi:10.1038/ajg.2015.233 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|